tirzepatide with affirm Weight Loss Program — Dual GIP/GLP-1 affirm tirzepatide Compound Tirzepatide

Laway BA, Malik TS, Khan SH, Rather TA

Kato M, Tani T, Terahara N, Tsuda T

These steps also encourage patients to build healthier lifestyle practices that will help them maintain their results

When vendors offer products at 50% below competitors, they typically cut corners on purity verification, use lower-grade synthesis methods, or ship degraded product that has been improperly stored

The SURMOUNT-4 trial (NEJM, 2023) demonstrated that continued treatment is necessary to maintain weight loss, as participants who discontinued tirzepatide after achieving weight loss regained significant weight during the withdrawal phase